Sign inJoin waitlistJoin the waitlist

Theresa Medina

Associate Professor · University of Colorado School of Medicine

Credentials: · · ·

History

University of Colorado School of Medicine
Present

Medical Oncology
2011–2013
Internal Medicine
2008–2011
University of Colorado School of Medicine
2004–2008

Research

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
The Lancet · 2024 · 686 citations
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
New England Journal of Medicine · 2025 · 482 citations
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology
Review · Journal of the National Comprehensive Cancer Network · 2022 · 415 citations

William Robinson
16 papers
Martin McCarter
13 papers
KL
Karl Lewis
10 papers
RG
Rene Gonzalez-Cotarelo
10 papers
Charles Cowey
6 papers
Divya Srivastava
5 papers
John Kirkwood
5 papers
John Lukens
5 papers
ST
Sajeve Thomas
5 papers
Sapna Patel
5 papers
AS
Amod Sarnaik
4 papers
Anthony Olszanski
4 papers

Grants

Improving Immunotherapies to Melanoma Through Modulation of MAIT Cell Activation by the Microbiome
National Cancer Institute · R21
PI · $399.8K · University of Colorado Denver
2020–2022

Clinical trials

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Site PI · Recruiting · Phase 2, Phase 3
TuHURA Biosciences, Inc.
2025–2032
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Site PI · Recruiting · Phase 3
Replimune, Inc.
2024–2031
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2021–2027